AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01114685 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: AlgaeCal-1
Description: Daily consumption of 7 capsules containing bone health ingredients
Study NCT01114685 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: AlgaeCal-2
Description: Taking 7 capsules a day for six months
Study NCT02733731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese Herbal Compound Ointment
Study NCT02733731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estriol
Study NCT02134626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 40mg / pill, one pill orally once a day for three months
Study NCT02584660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard-of-care
Description: Standard-of-care as per local protocol and defined by the medical team caring for the participant.
Study NCT01026727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPC-4326 plus a 2-3 drug optimized background regimen (OBR)
Description: For treatment arm #1: the MPC-4326 dose will be selected based on the inclusion of raltegravir (i.e., will be limited to 300 mg BID) or inclusion of darunavir (i.e., will be assigned 400 mg BID) in the OBR. If both raltegravir and darunavir are included in the OBR for a subject, the subject will be limited to 300 mg BID
Study NCT01026727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3-4 commercially available antiretroviral drugs
Description: For treatment arm #2: the antiretroviral regimen, dosage and frequency will be selected by the investigator.
Study NCT03359382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance or home exercise combined with eccentric exercise
Description: First year: Progressive resistance exercise (60-80% RM) combined with low intensity eccentric exercise (10%RM).~Second year: Progressive resistance exercise (60-80% RM) combined with progressive eccentric exercise (10-80% RM).~Third year:Home exercise combined with low intensity eccentric exercise (10% RM )
Study NCT01031784 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: holmium-166 poly lactic acid microspheres
Description: Intra arterial administration of radioactive Holmium 166 microspheres; 600 mg with a specific activity ranging from 1260 MBq per kilo liver weight to 5040 MBq in the highest dose
Study NCT01031784 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: holmium 166 microspheres
Description: intra arterial administration of holmium 166 microsphers in the hepatic artery
Study NCT02067208 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wedged insole
Description: Wedged insoles are designed to reduce frontal plane knee joint mechanical loads during gait. Specifically, they can alter the knee adduction moment during gait - a variable associated with progression of knee osteoarthritis. In the experimental arm of this study, participants will undergo biomechanical gait analysis to identify the wedged insole that reduces the moments the most. The two options are medial wedge, where the medial aspect of the foot is elevated relative to the lateral aspect, and the lateral wedge, where the lateral wedge is elevated relative to the medial aspect.
Study NCT01539616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZYH7
Description: ZYH7 4mg given once orally in the morning before breakfast, for 8 weeks.
Study NCT01539616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZYH7
Description: ZYH7 8 mg given once orally in the morning before breakfast, for 8 weeks.
Study NCT01539616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZYH7
Description: ZYH7 16 mg given once orally in the morning before breakfast, for 8 weeks.
Study NCT01539616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate
Description: Fenofibrate 160 mg given once orally in the morning before breakfast, for 8 weeks.
Study NCT01421693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone
Description: * ≥2-\<14 years - 60mg/kg/ once daily for 7 days~* 14 years and older - 2g once daily for 7 days~* Intravenous infusion. Vials of crystalline powder.
Study NCT04161170 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Digital integrated healthcare platform
Description: Digital Integrated Healthcare Platform Utilizing AI-based Dietary Management Solution and Real-time Continuous Glucose Monitoring system
Study NCT01421693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gatifloxacin
Description: Gatifloxacin 10 mg/kg/day for 7 days. Tablets for oral administration.
Study NCT01579383 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALD403
Description: Single Dose IV infusion on Day 1
Study NCT01579383 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALD403
Description: Single Dose subcutaneous injection on Day 1
Study NCT01579383 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Description: Single Dose subcutaneous injection on Day 1
Study NCT02122302 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CarePrep Online Health Assessment
Description: Patients can utilize a web-based self-assessment system to answer questions that address medical, psychological, social, behavioral, and quality-of-life issues that are relevant to pancreatic disease. Patients can enter and track their symptoms over the Internet from home or clinic. The system is also designed to gather clues to identify neuropathic pain, which occurs when the nervous system fails to properly regulate pain signals.
Study NCT02344758 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive lateral flow test for monitoring gluten intake
Study NCT02344758 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive lateral flow test for monitoring gluten intake
Study NCT02344758 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: gluten-free diet (GFD)
Study NCT02344758 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: gluten-containing diet
Study NCT05129917 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: consume 1 sachet per day for 14 day
Study NCT04161170 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital integrated healthcare platform
Description: Digital Integrated Healthcare Platform Utilizing AI-based Dietary Management Solution and Real-time Continuous Glucose Monitoring system
Study NCT04082286 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yttrium-90 labelled monoclonal antibody against CD66
Study NCT02134626 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Study NCT00895544 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine (whole virion, Vero cell derived)
Description: Dose A (Vietnam strain) for priming vaccination (Day 0) - Dose B (Indonesia strain) for booster vaccination (Day 360)
Study NCT00895544 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine (whole virion, Vero cell derived)
Description: Dose A (Vietnam strain) for priming vaccination (Day 0) - Dose A (Indonesia strain) for booster vaccination (Day 360)
Study NCT00938522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: Eligible patients were randomly assigned to cilostazol group or placebo group via the internet by the online randomization system. At least 12 h before the procedure, all patients received aspirin (300 mg loading if not taking before) and clopidogrel (300 mg loading dose). Patients in the cilostazol group received 200 mg of cilostazol (loading dose) 12 hours and 2 hours before the procedure, followed by 100 mg twice daily for 3 months.
Study NCT00938522 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eligible patients were randomly assigned to cilostazol group or placebo group via the internet by the online randomization system. At least 12 h before the procedure, all patients received aspirin (300 mg loading if not taking before) and clopidogrel (300 mg loading dose). Patients in the placebo group received 200 mg of placebo 12 hours and 2 hours before the procedure, followed by 100 mg twice daily for 3 months.
Study NCT01404455 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: HES 130/0.4 (VoluvenⓇ, Fresenius Kabi, Graz, Austria) 500mL loading
Description: HES 130/0.4 (VoluvenⓇ, Fresenius Kabi, Graz, Austria) 500mL loading during 15 minutes after induction of anesthesia
Study NCT01641822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZLI
Description: Aztreonam for Inhalation Solution (AZLI) 75 mg 3 times daily combined with diluent administered using an eFlow nebulizer
Study NCT01641822 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match AZLI
Description: Placebo to match AZLI 3 times daily combined with diluent administered using an eFlow nebulizer
Study NCT01641822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin inhalation solution
Description: Tobramycin inhalation solution (TIS) 300 mg 2 times daily using a PARI® LC Plus nebulizer and DeVilbiss Pulmo-Aide® air compressor
Study NCT01641822 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tobramycin inhalation solution
Description: Tobramycin inhalation solution (TIS) 300 mg 2 times daily using a PARI® LC Plus nebulizer and DeVilbiss Pulmo-Aide® air compressor
Study NCT02161926 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dietary restrictions
Description: Dietary restrictions during 8 weeks
Study NCT02161926 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary restrictions
Description: Dietary restrictions during 8 weeks
Study NCT04448353 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: vascuCAP
Description: adverse event and phenotype classification model
Study NCT03342625 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Instensity Focused Ultrasound
Description: High Intensity Focused Ultrasound guided by MRI
Study NCT04467125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eutectic Lidocaine Prilocaine
Description: Subjects randomized to EMLA receive one inch of EMLA cream placed at the removal site and then have an occlusive dressing placed. One hour later they have the Nexplanon device removed.
Study NCT04467125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous Lidocaine
Description: Subjects randomized to subcutaneous lidocaine have 1% lidocaine injected by the provider at the removal site in an amount decided on by the provider.
Study NCT00973492 — intervention group
Intervention type: OTHER
Intervention: functional insulinotherapy class
Description: The functional insulinotherapy class lasts for 4 days. It is taught by 2 nurses, 2 dieticians and 2 physicians to 6 to 10 patients.~On day 1, patients describe their difficulties with diabetes. Fast-acting insulin scales are elaborated from preprandial and postprandial blood glucose levels. At dinner, patients start a 24-hour glucose-fasting period to evaluate their need for basal insulin. Meals contain virtually no carbohydrates. Correcting doses of insulin are administered if preprandial glycemia is over 1.50 g/l or postprandial glycemia is over 2 g/l. Blood glucose levels must stay within normal values during the whole 24-hour period.~Carbohydrate management is taught during meals and every afternoon through workshops about dietetics. Patients also learn how to deal with hypoglycaemia, hyperglycaemia and physical activity.~A one-day follow-up takes place 3 months later.
Study NCT04460846 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alkaline water
Description: 1.5 liters per day
Study NCT04460846 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Reverse osmosis water
Description: 1.5 liters per day
Study NCT02880917 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS-Sham
Description: Sham tDCS will involve an identical electrode montage, with stimulation ceasing after a 30-second ramp-up period to provide equivalent scalp sensation.
Study NCT02880917 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS-Active
Description: tDCS was delivered using the anode electrode positioned over the left dorsolateral prefrontal cortex (DLPFE) and the cathode electrode at supra orbital right region. The electrodes were placed into a 25-35 cm2 square sponge immersed in saline solution for better current conductivity. Current density used was 2 mA and electrodes attached to the scalp were sustained by rubber band.
Study NCT02880917 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training
Description: . The cognitive training consisted of an online application of a Dual N-Back task .The Training will last for 8 days.
Study NCT02880917 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Cognitive training
Description: . The cognitive training consisted of an online application of a Dual N-Back task .The Training will last for 8 days.
Study NCT03514563 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI imaging
Description: MRI recordings of the craniofacial region
Study NCT03514563 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Optical scan
Description: Optical intraoral scans
Study NCT03514563 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 3D photography
Description: Facial stereophotogrammetry
Study NCT01476631 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking
Description: * 7 days prior to baseline participants must wear a blinded pedometer~* At baseline information on the blinded pedometer will downloaded to the computer for analysis as well as number of days worn and hours of wear. Sociodemographic, cancer risk factors, height/weight, fast blood draw to check levels on insulin, C-peptide, IL-6 and PEG-2 and questionnaires PPAQ, Exercise Confident Survey and Sallis Social Support Scale, Day/night; Home/Work, neighborhood safety, HINTS, IPAPS, CES-D, Brief COPE, Urban and Life Stress Scale.
Study NCT01402648 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Eviendep (CM&D Pharma Limited, UK)
Description: 175 mg milk thistle (fruit dry extract, 70% in silymarin)+ 20 mg flaxseed (dry extract, 40% in secoisolariciresinoldiglucoside)+750 mg non-starch, insoluble and indigestible fiber (6% in lignin). Provided in 5 g sachets, to be dissolved in half glass water, administered twice a day for 60 days on top of the common diet.
Study NCT01402648 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrins
Description: 900 mg maltodextrin+excipient as per the active comparator eviendep, up to 5 g/sachet
Study NCT02462993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aloe Vera
Description: Local drug delivery of aloe vera gel
Study NCT02280447 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1/3 IPV-Al SSI, manufactured by SSI, Denmark
Description: Intramuscular injection of 0.5 mL vaccine into deltoid muscle
Study NCT02280447 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1/5 IPV-Al SSI, manufactured by SSI, Denmark
Description: Intramuscular injection of 0.5 mL vaccine into deltoid muscle
Study NCT02280447 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1/10 IPV-Al SSI, manufactured by SSI, Denmark
Description: Intramuscular injection of 0.5 mL vaccine into deltoid muscle
Study NCT02280447 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IPV SSI, manufactured by SSI, Denmark
Description: Intramuscular injection of 0.5 mL vaccine into deltoid muscle
Study NCT01066962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darunavir/ritonavir QD + raltegravir BID
Description: darunavir 800 mg, i.e. 2 tablets of 400 mg once daily (QD)~ritonavir 100 mg, 1 tablet once daily (QD)~raltegravir 400 mg, 1 tablet twice daily (BID)
Study NCT00703885 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo (liquid) to be administered 1 hour prior to fMRI scan~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart.
Study NCT02625090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB0942
Description: * Active Substance: UCB0942~* Pharmaceutical form: Film-coated tablet~* Concentration: 25 mg, 100 mg or 200 mg~* Route of Administration: oral
Study NCT00983268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 1000 mg taken by mouth on the days of radiation only.
Study NCT00983268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Vorinostat will be given by mouth on the day of radiation and then Monday-Friday for two weeks after radiation in these 4 possible doses:~* Vorinostat,at 100 mg~* Vorinostat,at 200 mg~* Vorinostat, at 300 mg~* Vorinostat, at 400 mg
Study NCT00983268 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: High-dose hypofractionated radiotherapy consisting of 3000 cGy in 10 fractions, Monday-Friday for 2 weeks.
Study NCT00983268 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery to remove tumor
Description: Patients will be assessed for resectability within six weeks of the end of chemoradiation, if resectable, surgery will be performed.
Study NCT02488655 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echopulse
Description: HIFU Under ultrasound guidance
Study NCT03711279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210 plus Apatinib
Description: SHR-1210 200 mg q3w+ Apatinib 500 mg qd
Study NCT01066962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: darunavir/r QD + tenofovir/emtricitabine QD (fixed dose combination)
Description: darunavir 800 mg, i.e. 2 tablets of 400 mg once daily (QD)~ritonavir 100 mg, 1 tablet once daily (QD)~tenofovir/emtricitabine 245/200 mg, fixed dose combination, 1 tablet once daily (QD)
Study NCT05129917 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gojinsen® drinks
Description: consume 1 sachet per day for 14 day
Study NCT03711279 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADM plus IFO or IFO alone
Description: ADM 60 mg/m2 D1 + IFO 2 g/m2 D1-D4 q3w；if the cumulative doses of ADM were beyond 450 mg/m2, the monotherapy of IFO (2 g/m2 D1-D5 q3w) would be used.
Study NCT02285907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Macronutrient and Fiber Matched BEEF
Description: The participants will consume the macronutrient and fiber matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef (Cargill, KS). Soy fiber (Nutritional Designs, NY) was added to the BEEF meal to match total final content between meals.The participants will consume the serving size matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef patty (Cargill, KS).
Study NCT02285907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Macronutrient and Fiber Matched SOY
Description: The participants will consume the macronutrient and fiber matched SOY lunch on a single testing day. SOY contained 33% protein, 43% CHO, and 24% fat; the SOY meal contained 24 g of textured soy protein concentrate (Boca Foods, WI).
Study NCT02285907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serving Size Matched BEEF
Description: The participants will consume the serving size matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef patty (Cargill, KS).
Study NCT02285907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serving Size Matched SOY
Description: The participants will consume the serving size matched SOY lunch on a single testing day. SOY contained 24% protein, 49% CHO, and 24% fat; the SOY meal contained 14 g of textured soy protein concentrate (Boca Foods, WI).
Study NCT01596465 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-Study using MP3 Player
Description: Participants in the interventional arm of the study were given an MP3 player which contained eight, 15-second heart sound files (7 pathologic heart sound files and 1 normal heart sound file) alternated with nine leisure songs. MP3 players could play files in order or shuffle files in random order. Each heart sound file was introduced by the narrated phrase Identify this sound,, followed by 10 beats of a heart sound recording, then the narrated identification of the heart sound. Participants were asked to use the MP3 player in order to improve their auscultation skills as often as they could and asked to record their activities while listening, but were given no further training.
Study NCT01596465 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multimedia Lecture
Description: Following the pretest, participants in the control arm received a 1-hour multimedia lecture (Power Point) taught by the same faculty member (AGK), which reviewed the pathophysiology, exacerbating and relieving factors, as well as visual diagrams of the heart sounds. The normal and seven pathologic heart sounds were played for participants during the lecture for a total of 2 minutes through high-quality home stereo speakers, exposing learners to 1280 beats in the 1-hour session. Abnormal sounds were taught in groups of systolic, diastolic and extra sounds, and were first introduced by name, and then as unknowns using mixed practice in each of the three sections.
Study NCT00904085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxymorphone IR
Description: 5 mg
Study NCT00904085 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxymorphone IR
Description: 5 mg